BillionToOne, Inc.
BLLN
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $4.6B
$99.39
▼ -0.11%
P/E
193.14
Mkt Cap
$4.6B
52-Wk Range
$61.96–$150.44
52-Week Range
$61.96 - $150.44
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 8.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary single-molecule DNA counting technology
- Non-invasive diagnostic capabilities with high accuracy
- Comprehensive product suite for prenatal and oncology applications
- Early mover advantage in precision molecular diagnostics
Bear Case
2 risks
- Low volatility (beta 0.3).
- Growth premium of 4.4x vs Life Sciences Tools peers. Significant premium - requires sustained high growth to justify.
Growth
Moderate growth ahead
Expanding adoption of non-invasive prenatal screening
Value
Growth premium of 4.4x vs Life Sciences Tools peers. Significant premium - requires sustained high growth to justify.
Momentum
Stable
+2.3% over 3m
Quality
Excellent
High-growth business (99% revenue growth, 71% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying BLLN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 6, 2026
AUG 5, 2026
Reported EPS of $0.15 vs $0.18 consensus (-18.2% surprise). Revenue of $109.4M vs $109.2M expected (+0.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-18.2%
Revenue trend · last 8Q
—
—
—
+79%
+84%
+117%
+113%
+84%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$36.2M
$38.4M
$45.1M
$59.0M
$66.6M
$83.5M
$96.1M
$108.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
16.6%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$125.00
▲ +25.8% vs $99.39
Latest: Guggenheim · $125.00 · Jun 29, 2026
1 analyst covering
vs Industry
How BLLN stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related